| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KNG1 |
| Uniprot No | P01042-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-380aa |
| 氨基酸序列 | MASMTGGQQMGRGHHHHHHGNLYFQGGEFQESQSEEIDCNDKDLFKAVDA ALKKYNSQNQSNNQFVLYRITEATKTVGSDTFYSFKYEIKEGDCPVQSGK TWQDCEYKDAAKAATGECTATVGKRSSTKFSVATQTCQITPAEGPVVTAQ YDCLGCVHPISTQSPDLEPILRHGIQYFNNNTQHSSLFMLNEVKRAQRQV VAGLNFRMTYSIVQTNCSKENFLFLTPDCKSLWNGDTGECTDNAYIDIQL RIASFSQNCDIYPGKDFVQPPTKICVGCPRDIPTNSPELEETLTHTITKL NAENNATFYFKIDNVKKARVQVVAGKKYFIDFVARETTCSKESNEELTES CETKKLGQSLDCNAEVYVVPWEKKIYPTVNCQPLGMISLMK |
| 预测分子量 | 48 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KNG1重组蛋白的3篇代表性文献的简要总结(注：文献信息为模拟示例，实际研究请参考具体数据库)：
---
1. **标题**：*Recombinant human kininogen-1 inhibits angiogenesis and suppresses tumor growth in a murine model*
**作者**：Zhang L, et al.
**摘要**：本研究通过大肠杆菌表达系统制备重组人KNG1蛋白，发现其通过拮抗血管内皮生长因子(VEGF)信号通路抑制血管生成，并在小鼠肿瘤模型中显著减缓肿瘤生长，提示其潜在抗肿瘤应用价值。
---
2. **标题**：*Structural and functional characterization of recombinant high-molecular-weight kininogen (KNG1) domain 5 in inflammatory response*
**作者**：Müller F, et al.
**摘要**：作者解析了重组KNG1第五结构域(D5)的晶体结构，发现其通过结合中性粒细胞表面受体调控炎症反应，为开发靶向KNG1的抗炎药物提供了结构基础。
---
3. **标题**：*Recombinant KNG1-derived peptide as a novel anticoagulant: Mechanistic insights from in vitro studies*
**作者**：Chen Q, et al.
**摘要**：研究利用重组KNG1蛋白水解产生的活性肽段，证明其通过抑制接触激活途径(contact pathway)减少血栓形成，体外实验显示其抗凝效果优于传统肝素，且出血风险更低。
---
如需具体文献，建议在PubMed或Web of Science中检索关键词“recombinant KNG1 protein”或“recombinant kininogen-1”，并筛选近年高被引论文。
**Background of KNG1 Recombinant Protein**
Kininogen 1 (KNG1) is a multifunctional glycoprotein encoded by the *KNG1* gene, playing pivotal roles in coagulation, inflammation, and vascular homeostasis. It exists in two major isoforms: high-molecular-weight kininogen (HMWK) and low-molecular-weight kininogen (LMWK), derived from alternative splicing. HMWK is primarily involved in the intrinsic blood coagulation pathway, serving as a cofactor for the activation of kallikrein and factor XII (FXII), while LMWK is implicated in tissue-specific processes, including angiogenesis and apoptosis regulation.
Structurally, HMWK consists of six domains (D1–D6). Domains D1 and D2 bind prekallikrein and factor XI, D3 contains the bradykinin moiety, and D5–D6 mediate interactions with negatively charged surfaces, such as endothelial cells or pathogens. Upon cleavage by kallikrein, HMWK releases bradykinin, a potent vasoactive peptide that induces vasodilation, increases vascular permeability, and promotes pain signaling through G protein-coupled receptors (BK1R/BK2R).
Recombinant KNG1 protein is engineered to study these mechanisms *in vitro* or *in vivo*. It is produced using expression systems (e.g., mammalian, insect, or bacterial cells) to ensure proper post-translational modifications, particularly glycosylation, which is critical for its functional integrity. Applications include investigating thrombosis, hereditary angioedema, sepsis, and hypertension, as well as screening therapeutic agents targeting the kallikrein-kinin or coagulation systems.
Mutations in *KNG1* are linked to thrombotic disorders and inflammatory conditions, making recombinant KNG1 a valuable tool for elucidating disease pathways and developing diagnostics or biologics. Its role in crosstalk between coagulation and inflammation underscores its relevance in conditions like COVID-19. where dysregulated kinin systems contribute to pathogenesis.
×
